drugset
drugset / Trial / NCT07140523

A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA

NCT07140523 ↗

Phase 2 Recruiting 450 enrolled Sirius Therapeutics Co., Ltd.
RandomizedParallel-groupOpen-labelPrevention

Summary

This is a Phase 2, multicenter, randomized, open-label, parallel group, blinded endpoint evaluation, active-controlled, dose-finding study.This study is designed to compare the efficacy and safety of 3 dose levels of SRSD107 and enoxaparin 40 mg daily in subjects undergoing elective primary unilateral TKA.

Timeline

Start
2025-09-16
Primary completion
2026-06-30
Completion
2026-10-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Enoxaparin sodium Other / unclassified 40 mg Subcutaneous
Subject SRSD107 Small interfering RNA (siRNA) — Subcutaneous

Indications

venous thromboembolism